We could not find any results for:
Make sure your spelling is correct or try broadening your search.
-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy...
-INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas...
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in...
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the...
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the...
ProShares, a premier provider of ETFs, announced today forward and reverse share splits on 20 of its ETFs. The splits will not change the total value of a shareholder's investment...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -5.99 | -28.4155597723 | 21.08 | 22.4799 | 13.73 | 126401 | 16.97373344 | CS |
4 | -8.4 | -35.7598978289 | 23.49 | 26.2508 | 13.73 | 128771 | 20.77776825 | CS |
12 | 5.0696 | 50.592790707 | 10.0204 | 26.2508 | 10.0204 | 134518 | 19.17632944 | CS |
26 | 5.0696 | 50.592790707 | 10.0204 | 26.2508 | 10.0204 | 62989 | 19.17632944 | CS |
52 | 5.0696 | 50.592790707 | 10.0204 | 26.2508 | 10.0204 | 31746 | 19.17632944 | CS |
156 | 5.0696 | 50.592790707 | 10.0204 | 26.2508 | 10.0204 | 10526 | 19.17632944 | CS |
260 | 3.49 | 30.0862068966 | 11.6 | 26.2508 | 8.28 | 9479 | 16.84924491 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions